Close Menu

    Subscribe to Updates

    Get the latest information from JBUON.

    What's Hot

    Multiple Head and Neck Cancers: Molecular and Immunologic underpinnings

    July 12, 2025

    Clinical Staging, Histopathological Features and Treatment Outcomes in Malignant Melanoma: A 10-Year Retrospective Single-Center Study

    July 12, 2025

    Two Cases of Pancreatic Metastases from Renal Cell Carcinoma and Review of the Literature

    April 17, 2025
    Facebook X (Twitter) Instagram
    JBUONJBUON
    • How to Submit
    • Author Guidelines
    Facebook X (Twitter) Instagram
    SUBMIT
    • Home
    • Browse Issues
      • In Press
      • Current Issue
      • Archives
    • About Journal
      • Journal Information
      • Editorial Board
      • Bibliographic Listings
      • Editorial Policy
      • Ethics and Malpractice Statement
    • For Authors
      • How To Submit
      • Submit Article
      • Downloads
    • Contact
    JBUONJBUON
    Home»Issues»Volume 26, Issue 6»Fibroblast growth factor-23 in HER2 positive breast cancer: its expression and correlation with adjuvant EC->D+T treatment induced cardiotoxicity risk
    Volume 26, Issue 6

    Fibroblast growth factor-23 in HER2 positive breast cancer: its expression and correlation with adjuvant EC->D+T treatment induced cardiotoxicity risk

    December 1, 2021Updated:April 29, 20242 Mins Read
    Share
    Facebook Twitter Email

    Qian Zhang, Dengfeng Chen

    Department of Galactophore, Jingzhou Hospital, Yangtze University, Jingzhou 434000, China.

    Summary

    Purpose: The purpose of this study was to explore fibroblast growth factor-23 (FGF-23) expression and its predictive value on cardiotoxicity risk induced by adjuvant trastuzumab combined with chemotherapy in HER2 positive (HER2+ ) breast cancer patients.

    Methods: Enrolled were 105 HER2+ breast cancer patients about to receive adjuvant epirubicin combined with cyclophosphamide followed by docetaxel and trastuzumab (EC- >D+T) treatment after surgery. Their serum FGF-23 levels pre adjuvant therapy were determined by enzyme-linked immunosorbent assay (ELISA). Cardiotoxicity was monitored at 3 months (M), M6, M9, M12, and M15 after treatment.

    Results: The mean FGF-23 level was 333.7±130.3 pg/ml, and it was correlated with increased rates of hypertension (p=0.014) and chronic kidney disease (CKD) (p=0.025), decreased LVEF (r=-0.250, p=0.010), elevated cardiac troponin I (cTnl) (r=0.395, p<0.001) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) (r=0.367, p<0.001). Regarding cardiotoxicity rate, it was 0.0%, 0.0%, 1.9%, 11.4%, 17.1% and 19.0% at M0, M3, M6, M9, M12 and M15 respectively, which was stable at M0 and M3, while was obviously increased from M3 to M15. Compared with non-cardiotoxicity patients, FGF-23 level was higher in cardiotoxicity patients (410.1±165.2 vs. 315.7±114.6 pg/ml) (p=0.003), and it (p=0.021) was an independent risk factor predicting cardiotoxicity by multivariate logistic regression analysis, also had a good predictive value for cardiotoxicity risk (AUC: 0.664; 95%CI: 0.529-0.799) by receiver operating characteristic (ROC) curves.

    Conclusions: FGF-23 is upregulated and correlates with hypertension, CKD and poor cardiac function. Importantly, it is an independent risk factor predicting adjuvant EC->D+T treatment induced cardiotoxicity in HER2+ breast cancer patients.

    Key words: fibroblast growth factor-23, cardiotoxicity risk, human epidermal growth factor receptor-2, breast cancer, adjuvant EC->D+T treatment

    Full Text: PDF

    Original Article
    Previous ArticleCorrelation between clinicopathologic factors and recurrence score according to TAILOR x risk category in patients with hormone receptor positive early-stage breast cancer
    Next Article Risk reducing mastectomy in patients with and without gene mutation: experience in an Italian Breast Unit

    Related Articles

    Clinical Staging, Histopathological Features and Treatment Outcomes in Malignant Melanoma: A 10-Year Retrospective Single-Center Study

    Volume 28, 2025

    Exploration of Matrix Metalloproteinase-9 and Interleukin-8 in Breast Cancer Patients with No Lymph Node Involvement

    Volume 27, 2024

    Malignant Diseases as a Reason for Interventions by Emergency Medical Teams in Barajevo 2023

    Volume 27, 2024
    Don't Miss
    Volume 28, 2025

    Multiple Head and Neck Cancers: Molecular and Immunologic underpinnings

    July 12, 2025

    Eleni Litsou1*, Anna Goussia2, Vasileios Ragos3, Georgios Katiniotis4 and George Zarkavelis5 Author informationCitations 1Department of…

    Clinical Staging, Histopathological Features and Treatment Outcomes in Malignant Melanoma: A 10-Year Retrospective Single-Center Study

    July 12, 2025

    Two Cases of Pancreatic Metastases from Renal Cell Carcinoma and Review of the Literature

    April 17, 2025

    Exploration of Matrix Metalloproteinase-9 and Interleukin-8 in Breast Cancer Patients with No Lymph Node Involvement

    March 14, 2025
    Our Picks

    MicroRNA signatures landscape in renal cell carcinoma – related epithelial to mesenchymal transition

    December 1, 2021

    Chromosomal instability landscape in uveal melanoma

    December 1, 2021

    Biomarkers and common oral cancers: Clinical trial studies

    December 1, 2021

    Subscribe to Updates

    About Us
    About Us

    Journal of BUON (Print ISSN: 1107-0625, Electronic ISSN: 2241-6293) is an independent Open Access Journal, published by BAKIS Productions LTD, and appears exclusively on the internet. It is covered/indexed in Current Awareness in Biological Sciences (BIO-BASE), EMBASE/Excerpta Medica.
    We're accepting new manuscripts right now.

    Email Us: editorial_office@jbuon.com
    Contact: Available soon

    Editorial Picks

    MicroRNA signatures landscape in renal cell carcinoma – related epithelial to mesenchymal transition

    December 1, 2021

    Chromosomal instability landscape in uveal melanoma

    December 1, 2021

    Biomarkers and common oral cancers: Clinical trial studies

    December 1, 2021
    Get in Touch

    Editor-in-Chief
    Athanasios E. Athanasiou,
    Department of Medical Oncology,
    Metaxa Cancer Hospital, Botassi 51, 18537, Piraeus, Greece
    Editorial Office: editorial_office@jbuon.com

    Publishing support
    EManuscript Technologies
    # 9, First Floor, Vinnse Towers
    Wheeler Road Extension, St. Thomas Town, Bangalore 560 084, INDIA
    E: journals@emanuscript.in 
    W : www.emanuscript.in

     

    • Home
    • Author Guidelines
    • Site Map
    • Contact Us
    © 2025 JBUON Powered by EManuscript.

    Type above and press Enter to search. Press Esc to cancel.